AstraZeneca antidepressant is dumped after trial failures

Click to follow

AstraZeneca's already thin drugs pipeline was battered again yesterday when the pharmaceuticals firm admitted that an experimental antidepressant, once hailed as a potential worldwide multibillion dollar-a-year blockbuster, had failed its latest clinical trials and would be dumped.

It is another blow for Britain's second-biggest pharmaceuticals company, which last year called off late-stage trials of a prostate cancer drug, before writing off $445m (£281m) as it abandoned a new respiratory medicine for children.

Meanwhile Astra is facing a "patent cliff" as current blockbusters begin to face generic competition.

The drug maker will take a $50m impairment charge for the failure of TC-5214, which it licensed from the biotech Targacept three years ago for up to $1.2bn, dependent on hitting targets.

Astra had hoped that the drug would be the first in a new class of mental health medicines that work by calming nicotine receptors in the brain and it paid $200m up front for the rights.

Strong results from a Phase II study gave it pole position in AstraZeneca's prospective drugs portfolio, but TC-5214 failed the first of two late-stage trials last year, prompting an initial $96.5m writedown.

Now Astra has entirely abandoned its application to get the drug licensed for use as anadd-on therapy for patientswith depression.

AstraZeneca has just one drug in development, fostamatinib for arthritis, that analysts believe could be a big hit.

This month, the patent will expire on Seroquel, the anti-psychotic drug which brought in revenues of $5.7bn last year. Its ulcer treatment Nexium, which contributed $4.4bn to 2011 sales, faces competition in America in 2014 and its $6.6bn-a-year cholesterol-buster Crestor goes off patent in 2016.